araag2/HINT huggingface dataset:
Clinical trial NCT00099177 (phase 3, status: terminated)
Conditions: pain, bone neoplasm, neoplasm metastasis
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: ibandronate [bondronat], zoledronic acid
SMILES: CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O, OC(CN1C=CN=C1)(P(O)(O)=O)P(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  patients with malignant bone disease;

          -  patients with moderate to severe pain.

        Exclusion Criteria:

          -  patients who have received a bisphosphonate within 3 weeks from the signing of
             informed consent;

          -  patients receiving concurrent investigational therapy, or who have received
             investigational therapy within 30 days of the first scheduled day of dosing;

          -  untreated esophagitis or gastric ulcers;

          -  recent or pre-scheduled radiotherapy to bone;

          -  patients who are pregnant or breast-feeding.
Clinical trial NCT00280059 (phase 3, status: completed)
Conditions: epilepsy, partial
ICD codes: G40.111, G40.119, G40.211, G40.219, G40.101, G40.109, G40.201
Drugs: pregabalin, lamotrigine
SMILES: NCC1(CC(O)=O)CCCCC1, NC1=NC(N)=C(N=N1)C1=C(Cl)C(Cl)=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be diagnosed with partial epilepsy and have experienced at least 2
             partial seizures (simple partial, complex partial or partial seizure with secondary
             generalization) in the past year with one in the past 6 months.

        Exclusion Criteria:

          -  Treatable causes of seizures, for example identified etiologies including metabolic,
             neoplastic or active infectious origin.

          -  Primary generalized seizures.
Clinical trial NCT00093015 (phase 3, status: completed)
Conditions: kidney disease, diabetes mellitus, anemia
ICD codes: I12.9, N18.9, Q61.9, I12.0, D63.1, N18.1, N18.5, P70.2, O24.92, Z83.3, E10.65, E10.9, E11.65, E11.9, D53.2, D64.9, D46.4, D53.0, D53.9, D61.3, D61.9
Drugs: placebo, darbepoetin alfa
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Hemoglobin less than or equal to 11 g/dL

          -  History of Chronic Kidney Disease

          -  eGFR (estimated glomerular filtration rate) greater than or equal to 20 mL/min/1.73 m2
             and less than or equal to 60 mL/min/1.73 m2

          -  Tsat (transferrin saturation) greater than 15%

        Exclusion Criteria:

          -  Uncontrolled hypertension

          -  Erythropoietic protein use within 12 weeks of randomization
Clinical trial NCT00363896 (phase 3, status: completed)
Conditions: chronic obstructive pulmonary disease (copd)
ICD codes: G91.1, I42.1, N11.1, J05.0, G47.33, J44.9, N13.8
Drugs: aclidinium bromide, placebo
SMILES: OC(C(=O)O[C@H]1C[N+]2(CCCOC3=CC=CC=C3)CCC1CC2)(C1=CC=CS1)C1=CC=CS1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Males and females aged ≥ 40 years with a clinical diagnosis of moderate to severe
             stable COPD

        Exclusion Criteria:

          -  History or current diagnosis of asthma, recent respiratory tract infection or acute
             COPD exacerbation, life expectancy of less than 1 year, known symptomatic prostatic
             hypertrophy, bladder neck obstruction or narrow-angle glaucoma
Clinical trial NCT00314184 (phase 3, status: completed)
Conditions: bipolar disorder
ICD codes: F31.81, F31.89, F31.9, F25.0, F31.0, F31.31, F31.32
Drugs: quetiapine fumarate
SMILES: OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C12
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent

          -  18 years or older

          -  A diagnosis of Bipolar I Disorder

          -  Have a current manic, depressed or mixed episode

          -  Have had a manic, depressed or mixed episode during the last 26 weeks that was treated
             with quetiapine

          -  Female patients of childbearing potential must be using a reliable method of
             contraception

        Exclusion Criteria:

          -  Pregnancy

          -  Substance or alcohol dependence at enrollment

          -  Unstable thyroid function

          -  Unstable Diabetes

          -  Unstable or inadequately treated medical illness e.g., angina pectoris and
             hypertension

          -  Use of an experimental drug within 30 days of enrollment
Clinical trial NCT00085631 (phase 3, status: terminated)
Conditions: cervical cancer
ICD codes: M50.20, M50.21, M50.30, M50.31, M50.80, M50.81, M50.90
Drugs: cisplatin
SMILES: [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    study was closed because of slow accrual
  
Eligibility criteria:

        Inclusion criteria:

        Invasive cervical carcinoma (squamous, adeno or adenosquamous histologies, small cell
        histology excluded)

          -  age >18years

          -  International Federation of Gynecology and Obstetrics ((FIGO) stage IB2, IIA-IVA, FIGO
             stages IA, IB1 with positive pelvic lymph nodes or parametria either on imaging
             techniques or pathologically involved at the time of surgery.

        patients undergoing surgical removal of the cervix and uterus are not eligible, parametria
        either on imaging techniques or pathologically involved at the time • Performance status
        Eastern Cooperative Oncology Group(ECOG)/World Health Organisation (WHO) 0, 1 or
        >/=70%respectively White Blood count (WBC) ≥ 3,000, platelets ≥ 100,000, Absolute
        Neutrophil Count (ANC) > 1500

        • serum bilirubin ≤ 1.5 times upper limit of normal, transaminase ≤ 3 times upper limit of
        normal calculated creatinine clearance >60milliliters (mls)/liter ( Cockcroft) OR
        creatinine </= 2.0mgs% paraaortic adenopathy absent or 1.5 centimeter (cm) in greatest
        dimension on Computerised Tomography (CT) or Magnetic Resonance Imaging (MRI) scan;

        No history of myocardial infarction in the last 6 months no symptomatic angina pectoris
        negative pregnancy test in patients under 50 Hemoglobin >12.0 Gd/dl or >7.5 mmo;/L with
        transfusion if needed written written informed consent

        Exclusion criteria:

        surgical resection of the primary tumor (i.e. Total abdominal hysterectomy (TAH)/ Bilateral
        salpingoophorectomy (BSO)

          -  patients with pacemakers or implanted defibrillators

          -  patients with significant metallic foreign bodies (i.e. hip replacements, bone
             metallic rods,orthopedic plates, etc.)

          -  prior radiotherapy or chemotherapy
Clinical trial NCT00273338 (phase 3, status: terminated)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: calcitriol, docetaxel
SMILES: C[C@H](CCCC(C)(C)O)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    dsmb
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histopathologically or cytologically proven adenocarcinoma of the prostate

          -  Documented metastatic prostate adenocarcinoma

          -  Documented progression while on androgen ablation therapy detected by rising prostate
             specific antigen (PSA) and/or imaging

          -  Age >= 18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status <= 2

          -  Adequate hematologic, renal and hepatic function

          -  Life expectancy >= 3 months

        Exclusion Criteria:

          -  Prior chemotherapy, except estramustine

          -  Prior chemotherapy with docetaxel

          -  Prior isotope therapy (e.g., strontium-89, samarium-153, etc.)

          -  One or more contraindications to the use of corticosteroids

          -  History of cancer-related hypercalcemia
Clinical trial NCT00137735 (phase 3, status: completed)
Conditions: carpal tunnel syndrome
ICD codes: G56.00, G56.01, G56.02, G56.03
Drugs: gabapentin
SMILES: CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1
Eligibility criteria:

        Inclusion Criteria:

          -  Sensory symptoms over median nerve distribution for more than three months.

          -  Confirmatory electrophysiologic results defined as prolonged median nerve distal motor
             latencies (DML) > 4 ms or median-ulnar palmer sensory latency differences > 0.5 ms.

        Exclusion Criteria:

          -  Patients with evidence of severe CTS: fibrillation potentials or reinnervation on
             needle examination of the abductor pollicis brevis muscle or clinical examination
             showing wastage of the thenar muscles. (These patients were referred for surgical
             decompression on presentation.)

          -  Clinical or electrophysiological evidence of accompanying conditions that could mimic
             CTS or interfere with its evaluation, such as proximal median neuropathy, cervical
             radiculopathy, or significant polyneuropathy.

          -  Known epilepsy.

          -  Patients who have received previous steroid injection or oral steroid therapy for CTS.
Clinical trial NCT00313846 (phase 3, status: completed)
Conditions: osteoarthritis
ICD codes: M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: buprenorphine transdermal patch, placebo
SMILES: CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]1CC4=C5C(O[C@@H]2[C@@]35CCN1CC1CC1)=C(O)C=C4, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  clinical diagnosis of chronic osteoarthritis of the hip or knee for 1 year or longer.

          -  an average pain due to osteoarthritis of moderate, moderately-severe, or severe for
             the 14 days prior to enrollment.

        Exclusion Criteria:

          -  ingest opioid analgesics on a daily basis.

          -  ingest >2500 milligrams (mg) acetaminophen on a daily basis.

          -  require <20 mg or >80 mg of morphine (or opioid equivalents) per day for control of
             their osteoarthritis pain.

        Other protocol-specific exclusion/inclusion criteria may apply.
Clinical trial NCT00440167 (phase 3, status: unknown status)
Conditions: pancreatic cancer
ICD codes: C25.3
Drugs: gemcitabine, capecitabine, erlotinib
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, COCCOC1=CC2=C(C=C1OCCOC)C(NC1=CC(=CC=C1)C#C)=NC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Age between 18 and 75 years

          -  Histologically proven pancreatic cancer stage III or IV (T1-3 N1M0 or T1 3N0 1M1)

          -  No option for resection with curative intent

          -  At least one measurable or not measurable lesion (according to RECIST)

          -  No previous chemotherapy or other systemic tumor therapy

          -  No previous radiation

          -  Performance-Status 0-2 according to WHO/ECOG

          -  Life expectancy of at least 3 months

          -  Adequate kidney-, liver- and bone marrow function, defined as

          -  Absolute neutrophil count * 1,5 x 109/l

          -  Hemoglobin * 8 g/dl

          -  Thrombocytes * 100 x 109/l

          -  Bilirubin * 2 x upper norm (with liver mets < 5-fold)

          -  Serum Creatinine * 1,25 x upper norm

          -  Creatinine clearance > 30 ml/min (Cockroft/Gault)

          -  Transaminases * 2,5 x upper norm (with liver mets < 5-fold)

          -  Possibility of regular long-term follow-up

          -  Negative pregnancy test in women at childbearing age

          -  All patients must have signed an informed consent before study entry.

        Exclusion Criteria:

          -  Known secondary cancer other than curatively treated basalioma or carcinoma in situ of
             the cervix uteri

          -  Clinically unstable CNS-metastases

          -  Known hypersensitivity against study medication

          -  Severe impairment of renal function (creatinine clearance < 30 ml/min)

          -  Severe impairment of liver function (bilirubin > 2,0 x above upper norm, transaminases
             > 2,5 x upper norm, or with known liver metastasis >5 x upper norm)

          -  Clinically relevant disease of the cardiovascular system or other vital organs

          -  Known polyneuropathy

          -  Known DPD-deficiency (screening not required)

          -  Simultaneous treatment with the antiviral agent sorivudin or chemically related agents
             such as brivudin

          -  Pregnancy, lactation or lack of reliable contraception in women at childbearing age

          -  Mental disease, drug- or alcohol abuse

          -  Participation in another clinical trial within the last 4 weeks

          -  All other diseases which may prevent adequate participation in the trial

          -  Indication of lack of compliance with study regulations
Clinical trial NCT00492752 (phase 3, status: completed)
Conditions: carcinoma, hepatocellular
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: sorafenib (nexavar, bay43-9006), placebo
SMILES: CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Ages eligible for study: 18 years and above, Genders eligible for study: both

          -  Patients who have a life expectancy of at least 12 weeks

          -  Patients with advanced Hepatocellular carcinoma (HCC) (unresectable, and/or
             metastatic) which has been histologically or cytologically documented

          -  Patients must have at least one tumor lesion that meets both of the following criteria

               1. Accurately measured in at least one dimension according to Response Evaluation
                  Criteria in Solid Tumors (RECIST)

               2. Not been previously treated with local therapy

          -  Patients who have received local therapy, such as surgery, radiation therapy, hepatic
             arterial embolization, chemoembolization, radiofrequency ablation, percutaneous
             ethanol injection or cryoablation are eligible. Previously treated lesions will not be
             selected as target lesions. Local therapy must be completed at least 4 weeks prior to
             the baseline scan

          -  Patients who have an Eastern Co-operative Oncology Group (ECOG) Performance Status of
             0, 1, or 2

        Exclusion Criteria:

          -  Previous or concurrent cancer that is distinct in primary site or histology from HCC,
             EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder
             tumors (Ta [Noninvasive papillary carcinoma], Tis [Carcinoma in situ: "flat tumor"]&T1
             [Tumor invades subepithelial connective tissue]). Any cancer curatively treated > 3
             years prior to entry is permitted

          -  History of cardiac disease

          -  Active clinically serious infections

          -  Known history of human immunodeficiency virus (HIV) infection

          -  Known central nervous system (CNS) tumors including metastatic brain disease

          -  Patients with clinically significant gastrointestinal bleeding within 30 days prior to
             study entry
Clinical trial NCT01051531 (phase 3, status: completed)
Conditions: schizophrenia
ICD codes: F20.0, F20.1, F20.2, F20.3, F20.5, F20.89, F20.9
Drugs: paliperidone palmitate
SMILES: CC1=C(CCN2CCC(CC2)C2=NOC3=C2C=CC(F)=C3)C(=O)N2CCCC(O)C2=N1
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent to participate in the study obtained

          -  Signed informed consent to participate in the optional pharmacogenomic component of
             the study obtained (refusal to give consent for the pharmacogenomic component of the
             study does not exclude a patient from participation in the clinical study)

          -  Confirmation of diagnosis of schizophrenia according to the Diagnostic and Statistical
             Manual of Mental Disorders, 4th Edition (DSM-IV) within 5 years prior to screening

          -  Patient is willing and able to fill out self-administered questionnaires during the
             study

          -  confirmation that patient has been given an adequate dose of an appropriate oral
             antipsychotic for an adequate period of time before enrollment, but previous treatment
             is considered unsuccessful due to one or more of the following reasons: lack of
             efficacy, lack of tolerability or safety, lack of compliance and/or other reasons to
             switch to another antipsychotic medication

        Exclusion Criteria:

          -  The patient's psychiatric diagnosis is due to the direct pharmacological effects of a
             drug of abuse substance or medication, or is due to a general medical condition (eg,
             clinically notable hypothyroidism)

          -  The patient is treatment resistant in the judgment of the investigator

          -  The patient meets the DSM-IV definition of substance dependence (except for nicotine
             and caffeine) within 6 months prior to entry

          -  The patient has a previously defined hypersensitivity (anaphylaxis-type reaction) to
             risperidone or paliperidone or excipients

          -  The patient has received treatment with a long-acting injectable antipsychotic within
             3 injection cycles prior to baseline, received clozapine within 3 months prior to
             screening, received treatment with other investigational agents within 30 days of the
             screening visit, has participated in more than one investigational drug study in the
             past 12 months, or has planned use of other investigational drugs during the time
             frame of the study

          -  History or current symptoms of tardive dyskinesia, history of neuroleptic malignant
             syndrome, or evidence of clinically significant cardiovascular, renal, hepatic,
             gastrointestinal, neurological, endocrine, metabolic or pulmonary disease in the past
             6 months
Clinical trial NCT00337467 (phase 3, status: completed)
Conditions: human immunodeficiency virus (hiv) infections
ICD codes: Z21
Drugs: atazanavir + ritonavir
SMILES: ClC1=CC=CC(N2CCN(CCCCOC3=CC4=C(CCC(=O)N4)C=C3)CC2)=C1Cl
Eligibility criteria:

        Inclusion Criteria:

          -  On continued antiretroviral (ARV) treatment, with no discontinuation periods, for the
             previous 6 months (24 weeks).

          -  Absence of evidence or suspected virologic failure on antiretroviral therapy

          -  Absence of known primary mutations in the protease gene

          -  Only 1 highly active antiretroviral therapy (HAART) prior to current one

          -  HIV RNA < 50 copies/mL in the last 6 months (single blip below 200 c/mL allowed)

          -  On ATV/RTV +2 nucleoside reverse transcriptase inhibitors (NRTIs) (or 1 NRTI +
             tenofovir [TDF]) for at least 8 weeks before study entry, without treatment-limiting
             adverse effects

        Exclusion Criteria:

          -  Presence of a newly diagnosed HIV-related opportunistic infection or any medical
             condition requiring acute therapy at the time of enrollment.

          -  Active disease condition (e.g. moderate to severe hepatic impairment/active renal
             disease/history of clinically significant heart conduction disease)

          -  Patients with chronic hepatitis B receiving lamivudine (3TC), Tenofovir Disoproxil
             Fumarate (TDF) or emtricitabine (FTC).

          -  CD4 < 100 cells/mm3

          -  Grade IV laboratory values: Hemoglobin < 6.5 g/dL or white blood cells (WBC) <800/mmm3
             or absolute neutrophil count < 500/mm3, or platelets < 20,000/mm3 or diffuse
             petechiae.
Clinical trial NCT00269087 (phase 3, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: fluticasone propionate/salmeterol combination diskus
SMILES: [H][C@@]12C[C@@H](C)[C@](OC(=O)CC)(C(=O)SCF)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])C[C@H](F)C2=CC(=O)C=C[C@]12C
Eligibility criteria:

        Inclusion criteria:

          -  Diagnosis of COPD.

        Exclusion criteria:

          -  Diagnosis of asthma or an uncontrolled medical condition or respiratory disorder other
             than COPD.

          -  Other inclusion and exclusion criteria will be evaluated at the first study visit.
Clinical trial NCT00526643 (phase 3, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: gemcitabine, cisplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC
Reason stopped: 
    scarce enrolment and presentation of positive results of similar study in june 2012.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed diagnosis of advanced non small cell lung
             cancer, not amenable to surgical or curative radiation therapy (stage IIIB or IV);

          -  No prior or concomitant chemotherapy (adjuvant/neoadjuvant chemotherapy permitted if
             concluded at least one year prior to enrollment);

          -  ECOG performance status 2;

          -  Age: > or = 18 and < 70 years;

          -  Life expectancy at least 4 weeks;

          -  Normal bone marrow, hepatic and renal function defined as: neutrophils > or =
             2000/mm3, PLT > or = 100,000/mm3, Hb > or = 10.0 g/dl, Bilirubin > or = 1.5 times the
             upper normal limit (UNL), AST and ALT < or = 3 times the UNL (5 times in the presence
             of liver metastases), creatinine within normal limits;

          -  Signed informed consent.

        Exclusion Criteria:

          -  Active systemic infections;

          -  Severe concomitant illness (congestive heart failure, angina pectoris, myocardial
             infarction within previous 6 months, cardiac arrhythmias under treatment, severe
             arterial hypertension, severe or uncontrolled diabetes mellitus);

          -  Inadequate hepatic or renal function;

          -  Radiation therapy ongoing or concluded within two weeks prior to enrollment;

          -  Symptomatic cerebral metastases;

          -  Previous chemotherapy for advanced disease;

          -  Any condition that would, in the investigator's opinion, limit the patients ability to
             provide informed consent or to comply with study procedures;

          -  Pregnant or nursing females;

          -  Any malignancy within the past 5 years (except for adequately treated carcinoma in
             situ of the cervix or non melanoma skin cancer)